ESPEN 2013 - Late breaking abstract submission

Late Breaking Abstract

ESPEN13-1812

SERUM BIOMARKERS THAT PREDICT LEAN BODY MASS (LBM) LOSS OVER BEDREST (BR) IN OLDER ADULTS

S. H. Gawel ¹M. Luo ^2,*G. J. Davis ¹N. E. Deutz ³R. R. Wolfe ⁴N. K. Edens ²S. L. Pereira ²

¹Abbott Diagnostics, Illinois, ²Abbott Nutrition, Ohio, ³Geriatrics, Texas A&M University, Texas, ⁴Geriatrics, Univeristy of Arkansas for Medical Sciences, Arkansas, United States

Rationale: Loss of LBM during extended BR (i.e. hospitalization) contributes to functional decline and increased risk of mobility-disability in older adults.  This problem is unrecognized due to lack of practical diagnostic tools to measure LBM over hospitalization.  Identifying blood biomarkers that predict a hospitalized individual’s risk of losing LBM could increase awareness and allow for timely intervention.

Methods: Eighteen healthy subjects (age 60-76 y, 3 male,  15 female) were confined to 10 days of complete BR and received either placebo (8) or Ca-β-hydroxy-β-methylbutyrate (HMB) (10) over BR.  Fasting serum samples were obtained prior to the start of BR (D₁) and analyzed using multiplexed immunoassay array (RBM-Myriad).  LBM was assessed by DXA before and at the end of BR (D₁₀). Baseline biomarker data from both groups were merged, and multiple-hypotheses testing and partition analysis were used to identify baseline markers that predict LBM loss over BR.

Results: 187 markers were analyzed and 63 were excluded due to low detection levels. One pair of markers was found to correlate with percent change in LBM over BR: Tissue inhibitor of metalloprotease-1 (TIMP1) and Tenascin C (TNC) [R²=0.71, all subjects; R²= 0.76, females]. Subjects with TIMP1≥ 141 ng/ml at D₁ had larger losses of total LBM at D_10, whereas subjects with TIMP1< 141 and TNC≥ 461 ng/ml at D₁ did not lose total LBM over BR. Two additional markers were found to correlate with percent change in leg lean mass over BR: Matrix metalloprotease-3 (MMP3) and Apolipoprotein A2 (APOA2) [R²=0.59, females].  Females with MMP3< 6.93 ng/ml at D₁ were more likely to lose leg lean mass at D₁₀ compared with females with MMP3≥ 6.93 and ApoA2< 276 ng/ml at D₁ who did not lose muscle at D₁₀.

Conclusion: Panels of blood biomarkers may predict the likelihood for LBM loss over extended BR.  Validation of these markers in large clinical studies is needed. 

Disclosure of Interest: S. Gawel Shareholder of: AbbottM. Luo Shareholder of: AbbottG. Davis Shareholder of: AbbottN. Deutz: None DeclaredR. Wolfe Grant / Research Support from: AbbottN. Edens Shareholder of: AbbottS. Pereira Shareholder of: Abbott

Keywords: biomarkershospitalized elderly